TY - JOUR
T1 - Hyperkalemia during Treatment with HMG-CoA Reductase Inhibitor
AU - Edelman, S.
AU - Witztum, J. L.
AU - Grundy, Scott M
PY - 1989/5/4
Y1 - 1989/5/4
N2 - To the Editor: We recently observed a case of severe hyperkalemia in a patient with long-standing Type I diabetes, hypertension, and hyperlipidemia treated with lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, and lisinopril, an angiotensin-converting enzyme inhibitor. The patient was a 33-year-old white male physician with familial hypercholesterolemia, Type I diabetes mellitus since the age of 15, mild renal insufficiency with base-line creatinine and potassium levels of 1.7 mg per deciliter and 5.3 to 5.6 mmol per liter, respectively, and hypertension well controlled with lisinopril (50 mg per day). His base-line low-density lipoprotein (LDL) cholesterol level was 189 mg…
AB - To the Editor: We recently observed a case of severe hyperkalemia in a patient with long-standing Type I diabetes, hypertension, and hyperlipidemia treated with lovastatin, an inhibitor of 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase, and lisinopril, an angiotensin-converting enzyme inhibitor. The patient was a 33-year-old white male physician with familial hypercholesterolemia, Type I diabetes mellitus since the age of 15, mild renal insufficiency with base-line creatinine and potassium levels of 1.7 mg per deciliter and 5.3 to 5.6 mmol per liter, respectively, and hypertension well controlled with lisinopril (50 mg per day). His base-line low-density lipoprotein (LDL) cholesterol level was 189 mg…
UR - http://www.scopus.com/inward/record.url?scp=0024563816&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0024563816&partnerID=8YFLogxK
U2 - 10.1056/NEJM198905043201818
DO - 10.1056/NEJM198905043201818
M3 - Letter
C2 - 2710198
AN - SCOPUS:0024563816
SN - 0028-4793
VL - 320
SP - 1219
EP - 1220
JO - New England Journal of Medicine
JF - New England Journal of Medicine
IS - 18
ER -